News stories about Dynavax Technologies Corporation (NASDAQ:DVAX) have been trending somewhat positive on Sunday, according to Accern Sentiment Analysis. The research group identifies positive and negative media coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Dynavax Technologies Corporation earned a daily sentiment score of 0.19 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 45.269151971255 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

Here are some of the news stories that may have effected Accern Sentiment Analysis’s rankings:

A number of brokerages have weighed in on DVAX. Cowen and Company restated an “outperform” rating and issued a $30.00 price objective on shares of Dynavax Technologies Corporation in a report on Thursday. William Blair restated an “outperform” rating and issued a $30.00 price objective on shares of Dynavax Technologies Corporation in a report on Wednesday. Zacks Investment Research upgraded Dynavax Technologies Corporation from a “sell” rating to a “hold” rating in a report on Friday, August 4th. BidaskClub lowered Dynavax Technologies Corporation from a “buy” rating to a “hold” rating in a report on Monday, July 31st. Finally, Royal Bank Of Canada set a $7.00 price objective on Dynavax Technologies Corporation and gave the company a “hold” rating in a report on Wednesday, July 26th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company’s stock. Dynavax Technologies Corporation presently has an average rating of “Hold” and a consensus price target of $23.34.

Shares of Dynavax Technologies Corporation (NASDAQ DVAX) opened at 16.30 on Friday. The firm’s market capitalization is $892.38 million. The firm has a 50 day moving average price of $11.71 and a 200-day moving average price of $7.12. Dynavax Technologies Corporation has a 52 week low of $3.20 and a 52 week high of $19.60.

Dynavax Technologies Corporation (NASDAQ:DVAX) last released its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.50) by $0.09. Dynavax Technologies Corporation had a negative return on equity of 92.09% and a negative net margin of 1,323.99%. The firm had revenue of $0.11 million for the quarter, compared to the consensus estimate of $0.15 million. During the same period in the prior year, the business posted ($0.75) earnings per share. Equities research analysts predict that Dynavax Technologies Corporation will post ($1.58) EPS for the current fiscal year.

WARNING: This report was first reported by Watch List News and is the property of of Watch List News. If you are viewing this report on another website, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The correct version of this report can be accessed at

Dynavax Technologies Corporation Company Profile

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.

Insider Buying and Selling by Quarter for Dynavax Technologies Corporation (NASDAQ:DVAX)

Receive News & Ratings for Dynavax Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.